Search results for "VIE"

showing 10 items of 11648 documents

Epigenetic alterations in ameloblastomas : a literature review

2019

Background Ameloblastoma is a locally aggressive tumor, originated from odontogenic epithelium, and affects the jawbones with an elevated recurrence rate. The molecular mechanisms involved with the pathogenesis of this tumor remain undetermined. This review aimed to describe the current data regarding epigenetic alterations in ameloblastoma. Material and methods A systematized electronic search was performed in the English-language literature in three databases, combining the following keywords: ameloblastoma, epigenetic, methylation, noncoding RNA, histone acetylation. Results According to the gathered results of 11 studies in this review, epigenetic alterations could induce the developmen…

0301 basic medicineOral Medicine and PathologybiologyMechanism (biology)ReviewMethylationmedicine.diseaseNon-coding RNA03 medical and health sciences030104 developmental biology0302 clinical medicineHistoneAcetylation030220 oncology & carcinogenesisDNA methylationmedicinebiology.proteinCancer researchEpigeneticsAmeloblastomaGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

Parasites in the changing world – Ten timely examples from the Nordic-Baltic region

2020

Publisher's version (útgefin grein)

0301 basic medicineOriginal Research articleEpidemiologyHost030231 tropical medicineClimate change:Basale biofag: 470 [VDP]Baseline data030108 mycology & parasitologylcsh:Infectious and parasitic diseasesPeer reviewEuropeParasite03 medical and health sciencesSníklar0302 clinical medicineInfectious DiseasesGeography:Basic biosciences: 470 [VDP]Climate changelcsh:RC109-216ParasitologyLoftslagsbreytingarEnvironmental planningSelection (genetic algorithm)
researchProduct

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

2018

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow microenvironment that favors immune escape. The Programmed Death-1 (PD-1) pathway is associated with the regulation of T cell activation and with the apoptotic pathways of effector memory T cells. Specifically, the binding with PD-1 ligand (PD-L1) on the surface of tumor plasma cells down-regulates T cell-proliferation, thus contributing to the immune escape of tumor cells. In relapsed and/or refr…

0301 basic medicinePD-L1lcsh:Immunologic diseases. AllergyDurvalumabMini ReviewT-LymphocytesT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationT cellsPembrolizumabmedicine.disease_causeB7-H1 Antigen03 medical and health sciences0302 clinical medicineBone Marrowimmune dysregulationPD-L1PD-1Tumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyImmune dysregulation; Multiple myeloma; PD-1; PD-L1; T cells; Animals; B7-H1 Antigen; Bone Marrow; Humans; Multiple Myeloma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tumor MicroenvironmentMultiple myelomabiologybusiness.industryImmune dysregulationmedicine.diseasemultiple myeloma030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinCancer researchNivolumabbusinesslcsh:RC581-607Frontiers in Immunology
researchProduct

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

2020

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunothera…

0301 basic medicinePD-L1medicine.medical_treatmentimmune checkpoint inhibitorNanotechnologyReviewmacrophage03 medical and health sciencesMice0302 clinical medicineImmune systemDrug Delivery SystemsCancer immunotherapyPD-L1NeoplasmsPD-1MedicineAnimalsHumansNanotechnologytumor microenvironmentTreatment resistanceAdverse effecttoll like receptor (TLR)lcsh:QH301-705.5Tumor microenvironmentbiologybusiness.industryCancerGeneral Medicinemedicine.diseaseCombined Modality TherapyImmune therapy030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesissiRNAbiology.proteinCAR T cell therapymyeloid derived suppressor cells (MDSC)Immunotherapybusinessbi-specific antibody therapyCells
researchProduct

The Pharmacology of Visual Hallucinations in Synucleinopathies

2019

Visual hallucinations (VH) are commonly found in the course of synucleinopathies like Parkinson's disease and dementia with Lewy bodies. The incidence of VH in these conditions is so high that the absence of VH in the course of the disease should raise questions about the diagnosis. VH may take the form of early and simple phenomena or appear with late and complex presentations that include hallucinatory production and delusions. VH are an unmet treatment need. The review analyzes the past and recent hypotheses that are related to the underlying mechanisms of VH and then discusses their pharmacological modulation. Recent models for VH have been centered on the role played by the decoupling …

0301 basic medicineParkinson's diseaseParkinson's diseaseReviewPharmacologySerotonergicdefault mode network03 medical and health sciencesGlutamatergic0302 clinical medicineDopaminemedicinePharmacology (medical)Default mode networkPharmacologySynucleinopathiesDementia with Lewy bodiesbusiness.industrylcsh:RM1-950visual hallucinationmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisCholinergicSettore MED/26 - Neurologiasynucleinopathydementia with Lewy bodiesbusinessmedicine.drugFrontiers in Pharmacology
researchProduct

Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα

2017

Amyotrophic lateral sclerosis (ALS) is considered a multifactorial, multisystem disease in which inflammation and the immune system play important roles in development and progression. The pleiotropic cytokine TNFαis one of the major players governing the inflammation in the central nervous system and peripheral districts such as the neuromuscular and immune system. Changes in TNFαlevels are reported in blood, cerebrospinal fluid, and nerve tissues of ALS patients and animal models. However, whether they play a detrimental or protective role on the disease progression is still not clear. Our group and others have recently reported opposite involvements of TNFR1 and TNFR2 in motor neuron dea…

0301 basic medicinePathologymedicine.medical_specialtyAmyotrophic Lateral Sclerosis; Animals; Humans; Motor Neurons; T-Lymphocytes Regulatory; Tumor Necrosis Factor-alphamedicine.medical_treatmentT-LymphocytesCentral nervous systemImmunologyAmyotrophic lateral sclerosis inflammation TNFαInflammationReview ArticleT-Lymphocytes Regulatory03 medical and health sciences0302 clinical medicineImmune systemCerebrospinal fluidImmunology; Cell BiologyTNFαlcsh:PathologyMedicineAnimalsHumansAmyotrophic lateral sclerosisMotor Neuronsbusiness.industryTumor Necrosis Factor-alphaAmyotrophic Lateral SclerosisCell BiologyMotor neuronmedicine.diseaseRegulatory3. Good health030104 developmental biologymedicine.anatomical_structureCytokineinflammationImmunologyTumor necrosis factor alphamedicine.symptombusiness030217 neurology & neurosurgerylcsh:RB1-214
researchProduct

Aquaporins and Brain Tumors

2016

Brain primary tumors are among the most diverse and complex human cancers, and they are normally classified on the basis of the cell-type and/or the grade of malignancy (the most malignant being glioblastoma multiforme (GBM), grade IV). Glioma cells are able to migrate throughout the brain and to stimulate angiogenesis, by inducing brain capillary endothelial cell proliferation. This in turn causes loss of tight junctions and fragility of the blood–brain barrier, which becomes leaky. As a consequence, the most serious clinical complication of glioblastoma is the vasogenic brain edema. Both glioma cell migration and edema have been correlated with modification of the expression/localization …

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisAquaporinReviewBiologyBlood–brain barrieraquaporins (AQPs)Catalysislcsh:ChemistryInorganic Chemistry03 medical and health sciencesglioblastoma multiforme0302 clinical medicineEdemaGliomaSettore BIO/10 - Biochimicaaquaporins (AQPs); blood–brain barrier (BBB); brain tumors; extracellular vesicles (EVs); glioblastoma multiformemedicineBiomarkers TumorAnimalsHumansPhysical and Theoretical ChemistrySettore BIO/06 - Anatomia Comparata E Citologialcsh:QH301-705.5Molecular BiologySpectroscopyTight junctionBrain NeoplasmsSettore MED/27 - NeurochirurgiaOrganic ChemistryCancerGeneral Medicinemedicine.diseaseblood–brain barrier (BBB)Computer Science ApplicationsEndothelial stem cell030104 developmental biologymedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Blood-Brain Barrierbrain tumorsmedicine.symptomextracellular vesicles (EVs)Glioblastoma030217 neurology & neurosurgerybrain tumor
researchProduct

Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicell…

2016

This review is focused on the radiobiology of carbon ions compared to X-rays using multicellular models of tumors and normal mucosa. The first part summarizes basic radiobiological effects, as observed in cancer cells. The second, more clinically oriented part of the review, deals with radiation-induced cell migration and mucositis. Multicellular spheroids from V79 hamster cells were irradiated with X-rays or carbon ions under ambient or restricted oxygen supply conditions. Reliable oxygen enhancement ratios could be derived to be 2.9, 2.8, and 1.4 for irradiation with photons, (12)C(+6) in the plateau region, and (12)C(+6) in the Bragg peak, respectively. Similarly, a relative biological e…

0301 basic medicinePathologymedicine.medical_specialtyCancer Researchcell migrationMotilityReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicinerelative biological effectivenessRadioresistancemedicineRelative biological effectivenessorganotypic tumor and mucosa culturesparticle irradiationCell migrationOxygen enhancement ratio (OER)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensrelative biological effectiveness (RBE)030104 developmental biologymucositisOncologyradiobiologyCell cultureApoptosis030220 oncology & carcinogenesisCancer cellOxygen enhancement ratioBiophysicsoxygen enhancement ratioFrontiers in Oncology
researchProduct

Potential therapeutic uses of intraoral mesenchymal stem cells in other tissues of the body: A review

2020

Background Over the last few years, there has been a great advance in regenerative medicine, with various studies that have observed the ability to repair or regenerate dysfunctional tissues with the patient's own cells, such as with mesenchymal cells. In this area, mesenchymal stem cells (MSCs) from the oral cavity have attracted attention because of their easy access and multiple cellular differentiations. Multiple studies have shown the various clinical applications at the intraoral level, especially at the level of bone regeneration, but the potential applications of oral MSC at a systemic level have been scarcely described. Objective: The objective of this review was to describe the po…

0301 basic medicinePathologymedicine.medical_specialtyOral Medicine and Pathologybusiness.industryNervous tissueMesenchymal stem cellReviewBone tissueRegenerative medicineTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureLiver tissuemedicineStem cellbusinessBone regenerationGeneral DentistryUNESCO:CIENCIAS MÉDICAS030217 neurology & neurosurgeryJournal of Clinical and Experimental Dentistry
researchProduct